Risks and benefits of oral contraceptive pills

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 16, Issue 2, 2002, Pages 133-154

  D'Souza, Rachel E ^a   Guillebaud, John ^a  

^a Margaret Pyke Centre   (United Kingdom)

Author keywords

Benefits; Combined oral contraceptive pill; Oral contraceptive pill; Progestogen only pill; Risks

Indexed keywords

ESTROGEN; GESTAGEN; ORAL CONTRACEPTIVE AGENT;

ACNE; ALLERGIC REACTION; BONE MASS; BRAIN PSEUDOTUMOR; BREAST CANCER; BREAST FIBROADENOMA; CANCER RISK; CARBOHYDRATE METABOLISM; CEREBROVASCULAR ACCIDENT; CHICKENPOX; CHLOASMA; CHOREA; CLINICAL TRIAL; COLORECTAL CANCER; CORNEA EDEMA; DEPRESSION; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG OVERDOSE; DYSMENORRHEA; ECTOPIC PREGNANCY; ECZEMA; ENDOMETRIOSIS; ENDOMETRIUM CANCER; ERYTHEMA MULTIFORME; ERYTHEMA NODOSUM; FEMALE FERTILITY; FIBROCYSTIC BREAST DISEASE; HEART INFARCTION; HIRSUTISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; IRON DEFICIENCY ANEMIA; JAUNDICE; LIVER CELL CARCINOMA; MELANOMA; MENSTRUATION; META ANALYSIS; NAUSEA; ORAL CONTRACEPTION; OVARY CANCER; OVARY CYST; OVULATION INHIBITION; PAIN; PELVIC INFLAMMATORY DISEASE; PEMPHIGUS; PEPTIC ULCER; PREGNANCY; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; ROSACEA; SEBORRHEA; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TELANGIECTASIA; THYROID DISEASE; URINARY TRACT INFECTION; UTERINE CERVIX CANCER; VAGINA DISCHARGE; VENOUS THROMBOEMBOLISM; VOMITING; WEIGHT GAIN; WORLD HEALTH ORGANIZATION; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; DIGESTIVE SYSTEM DISEASE; DRUG INTERACTION; FEMALE; INFECTION; INFLAMMATION; LIBIDO; NEOPLASM; SKIN DISEASE;

CARDIOVASCULAR DISEASES; CONTRACEPTIVES, ORAL, COMBINED; CORNEAL EDEMA; DEPRESSIVE DISORDER; DIABETES MELLITUS; DIGESTIVE SYSTEM DISEASES; DRUG INTERACTIONS; FEMALE; HUMANS; INFECTION; INFLAMMATION; JAUNDICE; LIBIDO; NAUSEA; NEOPLASMS; RISK FACTORS; SKIN DISEASES; WEIGHT GAIN;

EID: 0036527038     PISSN: 15216934     EISSN: None     Source Type: Journal    
DOI: 10.1053/beog.2002.0266     Document Type: Article

References (82)

1. Guillebaud J. Contraception Today. London: Martin Dunitz, 2000.
2. Guillebaud J. Combined oral contraception. In Glasier A & Gebbie A (eds) Handbook of Family Planning pp 29-76. London: Churchill Livingstone, 2000.
3. Vessey MP. The Jephcott Lecture. An overview of the benefits and risks of combined oral contraceptives. In Mann RD (ed.) Oral Contraceptives and Breast Cancer pp 121-132. Carnforth, UK: Parthenon Publishing, 1989.
4. Blackburn RD, Cunkelman JA & Zlidar VM. Oral contraceptives - an update. Population Reports 2000; 1-40. Series A, no. 9.
5. Vessey MP. The Oxford Family Planning Association contraceptive study. Clinics in Obstetrics and Gynaecology 1984; 11(3): 743-758.
6. Kay CR. The RCGP oral contraception study. Clinics in Obstetrics and Gynaecology 1984; 11(3): 759-786.
7. Kols A, Rinehart W, Piotrow PT. et al Oral contraceptives in the 1980s. Population Reports 1982; A189-224. Series A, no. 6.
8. Nurses' Health Study History, 2001. Accessed 16 July. Available at www.channing.harvard.edu/nhs/hist.html.
9. Hatcher RA & Guillebaud J. The pill: combined oral contraceptives. In Hatcher RA, Trussell J, Stewert F et al (eds) Contraceptive Technology, pp 405-466. New York: Ardent Media, 1998. 17th edition.
10. World Health Organisation (WHO). A randomised, double blind study of six combined oral contraceptives. Contraception 1982; 25: 231-241.
11. Vessey MP, Smith MA & Yeates D. Return of fertility after discontinuation of oral contraceptives. British Journal of Family Planning 1986; 11: 120-124.
12. Brown S, Vessey M & Stratton I. The influence of method of contraception and cigarette smoking on menstrual patterns. British Journal of Obstetrics and Gynaecology 1988; 95: 905-910.
13. Vessey M, Painter R & Mant J. Oral contraception and other factors in relation to hospital referral for menstrual problems without known underlying cause: findings in a large cohort study. British Journal of Family Planning 1996; 22: 166-169.
14. Larsson G, Milsom I, Lindstedt G & Rybo G. The influence of a low-dose combined oral contraceptive on menstrual blood loss and iron status. Contraception 1992; 46(4): 327-334.
15. Milman N, Kirshoff M & Jorgensen T. Iron status markers, serum ferritin and hemoglobin in 1359 Danish women in relation to menstruation, hormonal contraception, parity, and postmenopausal hormone treatment. Annals of Hematology 1992; 65: 96-102.
16. Chan WY, Dawood MY & Fuchs F. Prostaglandins in primary dysmenorrhoea: comparison of prophylactic and non-prophylactic treatment with ibuprofen and use of oral contraceptives. American Journal of Medicine 1981; 70: 535-541.
17. Franceschi S. Oral contraceptive use and risk of cancer of the ovary and corpus uteri. In Hannaford PC & Webb AMC (eds) Evidence-guided Prescribing of the Pill, pp 135-144. London: The Parthenon Publishing Group, 1996.
18. International Agency for Research in Cancer (IARC). Monographs on the evaluation of carcinogenic risks to humans. Hormonal Contraception and Post Menopausal Hormonal Therapy. Lyons: WHO IARC, 1999, vol 72.
19. Cancer and Steroid Hormone Study of the Centres for Disease Control and the National Institute of Child Health and Human Development. The reduction in the risk of ovarian cancer associated with oral contraceptive use (CASH) 1987. New England Journal of Medicine 1987; 316: 650-655.
20. Cancer and Steroid Hormones (CASH). Combined oral contraceptive use and risk of endometrial cancer. Journal of the American Medical Association 1987; 257: 796-800.
21. Tuckey J. Combined oral contraception and cancer. British Journal of Family Planning 2000; 26: 237-240.
22. Whittlemore AS, Harris R & Intyre J. Collaborative Ovarian Cancer Group. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. American Journal of Epidemiology 1992; 136: 1184-1203.
23. Roberts H. Combined oral contraceptives: epidemiological studies and risk-benefit analysis. In Kubba A, Sanfilipp J. & Hampton N. (eds) Contraception and Office Gynaecology pp 49-60. London: Saunders, 1999.
24. Drife J. Benefits and risks of oral contraceptives. Advances in Contraception 1990; 6: 15-25.
25. Schlesselman JJ. Oral contraceptives and neoplasia of the uterine corpus. Contraception 1991; 43: 557-579.
26. Vessey M, Metcalfe A, Wells C et al. Ovarian neoplasms, functional ovarian cysts and oral contraceptives. British Medical Journal 1987; 294: 1518-1520.
27. Tayob Y, Adams J, Jacobs HS & Guillebaud J. Ultrasound demonstration of increased frequency of functional ovarian cysts in women using progestogen-only oral contraception. British Journal of Obstetrics and Gynaecology 1985; 92: 1003-1009.
28. Wolner-Hanssen. Relationship between oral contraceptives and pelvic inflammatory disease and associated sexually transmitted diseases. In Hannaford PC & Webb AMC (eds) Evidence-guided Prescribing of the Pill pp 175-180. London: The Parthenon Publishing Group, 1996.
29. Critchlow CW, Wolner-Hanssen P, Eschenbach DA et al. Determinants of cervical ectopia and of cervicitis: age, oral contraception, specific cervical infection, smoking and douching. American Journal of Obstetrics and Gynecology 1995; 173: 534-543.
30. Spinillo A, Gorini G, Piazzi G et al. The impact of oral contraception on chlamydial infection among patients with pelvic inflammatory disease. Contraception 1996; 54: 163-168.
31. Brinton LA, Vessey MP, Flavel R & Yeates D. Risk factors for benign breast disease. American Journal of Epidemiology 1981; 113: 203-214.
32. Martinez ME, Grodstein F & Giovannucci. A prospective study of reproductive factors, oral contraceptive use and risk of colorectal cancer. Cancer Epidemiology, Biomarkers and Prevention 1997; 6: 1-5.
33. Fernandez E, la Vecchia C, Franceschi S et al. Oral contraceptive use and risk of colorectal cancer. Epidemiology 1998; 9: 295-300.
34. Kleerekoper M, Brienza RS, Schultz LR & Johnson CC. Oral contraceptive use may protect against low bone mass. Archives of Internal Medicine 1991; 151: 1971-1976.
35. Cooper C, Hannaford P, Croft P & Kay CR. Oral contraceptive pill use and fractures in women: a prospective study. Bone 1993; 14: 41-45.
36. Vessey M, Mant J & Painter R. Oral contraception and other factors in relation to hospital referral for fracture: Findings in a large cohort study. Contraception 1998; 57: 231-235.
37. Ross RK, Pike MC, Vessey MP et al. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. British Medical Journal 1986; 293: 359-362.
38. Frank P & Kay CR. Incidence of thyroid disease associated with oral contraceptives. British Medical Journal 1978; 2: 1513.
39. Vessey M, Villard-Mackintosh L, McPherson K & Yeates D. Thyroid disorders and oral contraceptives. British Journal of Family Planning 1987; 13: 124-127.
40. Royal College of General Practitioners Oral Contraception Study. Reduction in the incidence of rheumatoid arthritis associated with oral contraceptives. Lancet 1978; 1: 569-570.
41. Vessey M, Villard-Mackintosh L & Yeates D. Oral contraceptives, cigarette smoking and other factors in relation to arthritis. Contraception 1987; 35: 457-464.
42. Pladevall-Vila M, Delclos GL, Varas C et al. Controversy of oral contraceptives and risk of rheumatoid arthritis: meta-analysis of conflicting studies and review of conflicting meta-analyses with special emphasis on analysis of heterogeniety. American Journal of Epidemiology 1996; 144: 1-14.
43. Knijff SCM, Goorissen EM, Velthuis-te Wierik EJM et al Summary of Contraindications to Oral Contraceptives. London: Parthenon Publishing, 2000.
44. Robinson GE, Burren T, Mackie IJ et al. Changes in haemostasis after stopping the combined contraceptive pill: implications for major surgery. British Medical Journal 1991; 302: 269-271.
45. Walker AM. Newer oral contraceptives and the risk of venous thromboembolism. Contraception 1998; 57: 169-181.
46. Medicines Commission. Combined oral contraceptives containing desogestrel or gestodene and the risk of venous thromboembolism. Current Problems in Pharmacovigilance 1999; 25: 12.
47. Macki IJ, Piegsa K, Furs S-A et al Protein S levels are lower in women receiving desogestrel - containing combined oral contraceptives than in women receiving levonorgestrel - containing COCs at steady state and on cross-over. British Journal of Haematology 2001; 113: 898-904.
48. Fraser IS. Progestogen-only contraception. In Glasier A & Gebbie A (eds) Handbook of Family Planning pp 77-103. London: Churchill Livingstone, 2000.
49. World Health Organisation (WHO). Cardiovascular disease and steroid hormone contraception: Report of a WHO scientific group. Geneva: WHO, 1997 p90. WHO Technical Report Series No. 877.
50. Petitti DB, Sidney S & Queensberry CP. Oral contraceptive use and myocardial infarction. Contraception 1998; 57: 143-155.
51. Dunn N, Thorogood M, Faragher B et al. Oral contraceptives and myocardial infarction: results of the MICA caes-control study. British Medical Journal 1999; 318: 1579-1584.
52. World Health Organisation (WHO). Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. Lancet 1997; 349: 1202-1209.
53. Schwingl PJ, Ory HW & Visness CM. Estimates of the risk of cardio-vascular death attributable to low-dose oral contraceptives in the United States. American Journal of Obstetrics and Gynecology 1999; 180: 241-249.
54. Poulter NR, Chang CL, Farley TM et al. Ischaemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study. WHO collaborative study of cardiovascular disease and steroid hormone contraception. Lancet 1996; 348: 498-505.
55. Thorogood M. Stroke and steroid hormonal contraception. Contraception 1998; 57: 157-167.
56. Chang CL, Donaghy M & Poulter N. Migraine and stroke in young women: a case-control study. British Medical Journal 1999; 318: 13-18.
57. Becker WJ. Use of oral contraceptives in patients with migraine. Neurology 1999; 53 (Suppl 1): S19-S25.
58. World Health Organisation (WHO). Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multicentre, case-control study. Lancet 1996; 348: 505-510.
59. Shen Q, Lin D, Jiang X et al Blood pressure changes and hormonal contraceptives. Contraception 1994; 50: 131-141.
60. Chasan-Taber L, Willett WC, Manson JE et al. Prospective study of oral contraceptives and hypertension among women in the United States. Circulation 1996; 94: 483-489.
61. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives. Lancet 1996; 347: 1713-1727.
62. Irwin KL. The association between oral contraceptive use and neoplasia of the cervix, vagina and vulva. In Hannaford PC & Webb AMC (eds) Evidence-Guided Prescribing of the Pill pp 145-156. London: The Parthenon Publishing Group, 1996.
63. Zondervan KT, Carpenter LM, Painter R & Vessey MP. Oral contraceptives and cervical cancer - further findings from the Oxford Family Planning Association contraceptive study. British Journal of Cancer 1996; 73: 1291-1297.
64. Buiatti E. Cervical smears: when to start and how often to do. In Hannaford PC & Webb AMC (eds) Evidence-Guided Prescribing of the Pill pp 157-166. London: The Parthenon Publishing Group, 1996.
65. Rosenburg L. The risk of liver neoplasia in relation to combined oral contraceptive use. Contraception 1991;43:643-652.
66. Neuberger J, Forman D, Doll R & Williams R. Oral contraceptives and hepatocellular carcinoma. British Medical Journal 1986; 292: 1355-1357.
67. Waetjen LE & Grimes DA. Oral contraceptives and primary liver cancer: temporal trends in three countries. Obstetrics and Gynaecology 1996; 88: 945-949.
68. Godet PG, May GR & Sutherland LR. A meta-analysis of the role of oral contraceptive agents in inflammatory bowel disease. Gut 1995; 37: 668-673.
69. World Health Organisation (WHO). Improving access to quality care in family planning: medical eligibility criteria for contraceptive use (revised). Geneva: WHO 2001.
70. Talwar PP & Berger GS. The relation of body weight to side effects associated with OC. British Medical Journal 1977; 1: 1637-1638.
71. Endrikat J, Jaques MA, Mayerhofer M et al. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 μg ethinylestradiol/75 μg gestodene and 20 μg ethinylestradiol/l50 μg desogestrel, with respect to efficacy, cycle control and tolerance. Contraception 1995; 52: 229-235.
72. Vessey MP, McPherson K, Lawless M & Yates D. Oral contraception and serious psychiatric illness: absence of an association. British Journal of Psychiatry 1985; 146: 45-49.
73. Graham CA, Ramos R, Bancroft J et al The effects of steroidal contraceptives on the well-being and sexuality of women: A double blind, placebo-controlled, two-centre study of combined and progestogen-only methods. Contraception 1995; 52: 327-335.
74. The clinical enquiry service; benign intracranial hypertension. British Journal of Family Planning 2000; 26: 169.
75. Davidson F & Oates J. The pill does not cause 'thrush'. British Journal of Obstetrics and Gynaecology 1985; 92: 1265-1266.
76. The Royal College of General Practitioners. An interim report from the Oral Contraception Study of the Royal College of General Practitioners. Oral Contraceptives and Health. London: Pitman Medical, 1974.
77. Green A. Oral contraceptives and skin neoplasia. Contraception 1991; 43: 653-666.
78. Beral V, Hermon C, Kay C et al. Mortality associated with oral contraceptives; 25 year follow-up of cohort of 46 000 women from Royal College of General Practitioners Oral Contraception Study. British Medical Journal 1999; 318: 96-100.
79. Hannaford P & Webb A. Evidence-guided prescribing of combined oral contraceptives: consensus statement. Contraception 1996; 54: 125-129.
80. Family Planning Association. Your guide to the combined pill; helping you choose the method of contraception that is best for you'. London: FPA, 2000. February.
81. Family Planning Association, Your guide to the progestogen only pill; helping you choose the method of contraception that is best for you'. London: FPA, 2000. February.
82. Tanis BC, van der Bosch MA, Kemmesen JM et al Oral contraceptives and the risk of myocardial infarction. New England Journal of Medicine 2000; 345: 1787-1793